BVF Inc. IL purchased a new stake in Spero Therapeutics Inc (NASDAQ:SPRO) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,029,185 shares of the company’s stock, valued at approximately $12,093,000. Spero Therapeutics accounts for about 1.5% of BVF Inc. IL’s investment portfolio, making the stock its 22nd biggest holding. BVF Inc. IL owned approximately 7.16% of Spero Therapeutics as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Dean Capital Investments Management LLC bought a new position in Spero Therapeutics during the fourth quarter worth $118,000. Deutsche Bank AG bought a new position in Spero Therapeutics during the fourth quarter worth $155,000. California Public Employees Retirement System bought a new position in Spero Therapeutics during the fourth quarter worth $294,000. BlackRock Inc. bought a new position in Spero Therapeutics during the fourth quarter worth $2,830,000. Finally, AWM Investment Company Inc. bought a new position in Spero Therapeutics during the fourth quarter worth $4,112,000. 46.28% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Tuesday, January 30th. Oppenheimer set a $30.00 price target on shares of Spero Therapeutics and gave the stock a “buy” rating in a research note on Thursday, January 11th. Cantor Fitzgerald reiterated a “buy” rating and set a $27.00 price target on shares of Spero Therapeutics in a research note on Monday. Finally, ValuEngine upgraded shares of Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $24.25.
NASDAQ SPRO traded down $0.05 on Monday, hitting $14.20. 8,322 shares of the company were exchanged, compared to its average volume of 30,068. Spero Therapeutics Inc has a 1-year low of $9.66 and a 1-year high of $15.40.
COPYRIGHT VIOLATION NOTICE: This report was posted by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://theenterpriseleader.com/2018/04/02/bvf-inc-il-invests-12-09-million-in-spero-therapeutics-inc-spro.html.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.